tetano
Editor, Senior Moderator
J Virol
. 2020 Oct 14;JVI.01277-20.
doi: 10.1128/JVI.01277-20. Online ahead of print.
A novel mechanism underlying antiviral activity of an influenza virus M2-specific antibody
Rashid Manzoor[SUP] 1 [/SUP], Nao Eguchi[SUP] 1 [/SUP], Reiko Yoshida[SUP] 1 [/SUP], Hiroichi Ozaki[SUP] 2 [/SUP], Tatsunari Kondoh[SUP] 1 [/SUP], Kosuke Okuya[SUP] 1 [/SUP], Hiroko Miyamoto[SUP] 1 [/SUP], Ayato Takada[SUP] 3 4 5 [/SUP]
Affiliations
Abstract
Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as an attractive vaccine antigen to confer cross-protective immunity against multiple subtypes of IAVs. However, antiviral mechanisms of M2-specific antibodies are not fully understood. Here, we report the molecular basis of antiviral activity of M2-specific monoclonal antibody (mAb), rM2ss23. We first found that rM2ss23 inhibited A/Aichi/2/1968 (H3N2) (Aichi) but not A/PR/8/1934 (H1N1) (PR8) replication. rM2ss23 altered the cell surface distribution of M2, likely by crosslinking the molecules, and interfered with colocalization of HA and M2 resulting in reduced budding of progeny viruses. However, these effects were not observed for another strain, PR8, despite the binding capacity of rM2ss23 to PR8 M2. Interestingly, HA was also involved in the resistance of PR8 to rM2ss23. We also found that two amino acid residues at positions 54 and 57 in the M2 cytoplasmic tail were critical for the insensitivity of PR8 to rM2ss2. These findings suggest that disruption of the M2-HA colocalization on infected cells and subsequent reduction of virus budding is one of the principal mechanisms of antiviral activity of M2-specific antibodies and that anti-M2 antibody-sensitive and -resistant IAVs have different properties of the interaction between M2 and HA.IMPORTANCE Although the IAV HA is the major target of neutralizing antibodies, most of the antibodies are HA subtype-specific, restricting the potential of HA-based vaccines. On the contrary, the IAV M2 protein has been studied as a vaccine antigen to confer cross-protective immunity against IAVs with multiple HA subtypes since M2 is antigenically conserved. Although a number of studies highlight the protective role of anti-HA neutralizing and non-neutralizing antibodies, precise information on the molecular mechanism of action of M2-specific antibodies is still obscure. In this study, we found that an anti-M2 antibody interfered with the HA-M2 association, which is important for efficient budding of progeny virus particles from infected cells. The antiviral activity was IAV strain-dependent despite the similar binding capacity of the antibody to M2, and interestingly, HA was also involved in the susceptibility to the antibody. Our data provides a novel mechanism underlying antiviral activity of M2-specific antibodies.
Copyright ? 2020 American Society for Microbiology.
. 2020 Oct 14;JVI.01277-20.
doi: 10.1128/JVI.01277-20. Online ahead of print.
A novel mechanism underlying antiviral activity of an influenza virus M2-specific antibody
Rashid Manzoor[SUP] 1 [/SUP], Nao Eguchi[SUP] 1 [/SUP], Reiko Yoshida[SUP] 1 [/SUP], Hiroichi Ozaki[SUP] 2 [/SUP], Tatsunari Kondoh[SUP] 1 [/SUP], Kosuke Okuya[SUP] 1 [/SUP], Hiroko Miyamoto[SUP] 1 [/SUP], Ayato Takada[SUP] 3 4 5 [/SUP]
Affiliations
- PMID: 33055251
- DOI: 10.1128/JVI.01277-20
Abstract
Protective immunity against influenza A viruses (IAVs) generally depends on antibodies to the major envelope glycoprotein, hemagglutinin (HA), whose antigenicity is distinctive among IAV subtypes. On the other hand, the matrix 2 (M2) protein is antigenically highly conserved and has been studied as an attractive vaccine antigen to confer cross-protective immunity against multiple subtypes of IAVs. However, antiviral mechanisms of M2-specific antibodies are not fully understood. Here, we report the molecular basis of antiviral activity of M2-specific monoclonal antibody (mAb), rM2ss23. We first found that rM2ss23 inhibited A/Aichi/2/1968 (H3N2) (Aichi) but not A/PR/8/1934 (H1N1) (PR8) replication. rM2ss23 altered the cell surface distribution of M2, likely by crosslinking the molecules, and interfered with colocalization of HA and M2 resulting in reduced budding of progeny viruses. However, these effects were not observed for another strain, PR8, despite the binding capacity of rM2ss23 to PR8 M2. Interestingly, HA was also involved in the resistance of PR8 to rM2ss23. We also found that two amino acid residues at positions 54 and 57 in the M2 cytoplasmic tail were critical for the insensitivity of PR8 to rM2ss2. These findings suggest that disruption of the M2-HA colocalization on infected cells and subsequent reduction of virus budding is one of the principal mechanisms of antiviral activity of M2-specific antibodies and that anti-M2 antibody-sensitive and -resistant IAVs have different properties of the interaction between M2 and HA.IMPORTANCE Although the IAV HA is the major target of neutralizing antibodies, most of the antibodies are HA subtype-specific, restricting the potential of HA-based vaccines. On the contrary, the IAV M2 protein has been studied as a vaccine antigen to confer cross-protective immunity against IAVs with multiple HA subtypes since M2 is antigenically conserved. Although a number of studies highlight the protective role of anti-HA neutralizing and non-neutralizing antibodies, precise information on the molecular mechanism of action of M2-specific antibodies is still obscure. In this study, we found that an anti-M2 antibody interfered with the HA-M2 association, which is important for efficient budding of progeny virus particles from infected cells. The antiviral activity was IAV strain-dependent despite the similar binding capacity of the antibody to M2, and interestingly, HA was also involved in the susceptibility to the antibody. Our data provides a novel mechanism underlying antiviral activity of M2-specific antibodies.
Copyright ? 2020 American Society for Microbiology.